Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients

Thursday, January 4, 2018 1 min read

Key Takeaway: Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients

Full Press Release Details

Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients.